Amarin’s Value Could Plunge If Heart Drug Patent Suit Is Lost

(Bloomberg) -- Analysts have cautioned Amarin Corp.’s share price could be cut in half after a key patent decision for its cardiovascular medicine Vascepa, expected in March.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.